Drug Trial Radar · NCT05568888
Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )
Last checked: Nov 19, 2026Latest source record: Dec 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,366
Actual
Start
Mar 28, 2023
Primary completion
Oct 29, 2024
Study completion Oct 29, 2024
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Oct 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, large simple trial to investigate the efficacy and safety of a single intravenous (IV) infusion of BE1116 in subjects who have traumatic injury, with confirmed or suspected acute major bleeding and / or predicted to receive a large volume blood product transfusion.
Conditions
- Traumatic Injury
Interventions
BE1116Drug
4-Factor Prothrombin Complex administered by intravenous (IV) infusion
PlaceboDrug
Administered by IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants With All-cause 6-hour MortalityTime frame: Up to 6 hours after randomization
Locations
113 sites in 3 countries. Site status is shown where the registry gives one.
UAB Hospital
Birmingham, Alabama
University of South Alabama
Mobile, Alabama
Chandler Regional Medical Center
Chandler, Arizona
Banner - University Medical Center Phoenix
Phoenix, Arizona
Valleywise Medical Center
Phoenix, Arizona
St. Joseph's Hospital and Medical Center
Phoenix, Arizona
HonorHealth Scottsdale Osborn Medical Center
Scottsdale, Arizona
University Medical Center Tucson
Tucson, Arizona
UAMS Medical Center
Little Rock, Arkansas
LAC+USC Medical Center
Los Angeles, California
Ronald Reagan UCLA Medical Center
Los Angeles, California
Riverside University Health System Medical Center
Moreno Valley, California
UC Irvine
Orange, California
UC Davis Medical Center
Sacramento, California
UC San Diego Medical Center
San Diego, California
San Francisco General Hospital and Trauma Center
San Francisco, California
University of Colorado Aurora
Aurora, Colorado
UC Health Memorial Hospital Central
Colorado Springs, Colorado
Denver Health and Hospital Authority
Denver, Colorado
Medical Center of the Rockies
Loveland, Colorado
Yale New Haven Hospital
New Haven, Connecticut
MedStar Washington Medical Center
Washington D.C., District of Columbia
George Washington University Hospital
Washington D.C., District of Columbia
UF Health Jacksonville
Jacksonville, Florida
University of Miami/Ryder Trauma Center
Miami, Florida
Grady Memorial Hospital
Atlanta, Georgia
Augusta University Medical Center
Augusta, Georgia
Northeast Georgia Health System
Gainesville, Georgia
Atrium Health - Medical Center of central Georgia
Macon, Georgia
University of Chicago Medical Center
Chicago, Illinois
Indiana University Methodist Hospital
Indianapolis, Indiana
St. Vincent's Hospital
Indianapolis, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Kansas University Medical Center
Kansas City, Kansas
University of Kentucky Albert B. Chandler Hospital
Lexington, Kentucky
University of Louisville Hospital
Louisville, Kentucky
University Medical Center of New Orleans
New Orleans, Louisiana
LSU Health Shreveport
Shreveport, Louisiana
Tufts Medical Center
Boston, Massachusetts
University Hospital
Ann Arbor, Michigan
Showing 40 of 113 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.